1. Home
  2. NEXM vs BNR Comparison

NEXM vs BNR Comparison

Compare NEXM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexMetals Mining Corp.

NEXM

NexMetals Mining Corp.

HOLD

Current Price

$2.22

Market Cap

79.1M

Sector

N/A

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$8.08

Market Cap

76.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXM
BNR
Founded
N/A
2014
Country
Canada
China
Employees
204
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
76.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NEXM
BNR
Price
$2.22
$8.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.6K
25.3K
Earning Date
05-20-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.20
$3.11
52 Week High
$6.75
$41.72

Technical Indicators

Market Signals
Indicator
NEXM
BNR
Relative Strength Index (RSI) 40.44 37.97
Support Level $2.29 $8.04
Resistance Level $2.62 $9.90
Average True Range (ATR) 0.18 0.83
MACD -0.03 0.31
Stochastic Oscillator 20.00 46.26

Price Performance

Historical Comparison
NEXM
BNR

About NEXM NexMetals Mining Corp.

NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: